Exosomes enhance the spread of tumor metastasis
The quantity of exosomes in circulation is indirect correlation with cancer progression
What if exosomes could beeliminated from circulation?
The Aethlon Hemopuriﬁer®The ﬁrst therapeutic candidate to eliminate cancer exosomes from circulation
The Aethlon Hemopuriﬁer®• Provides a therapeutic ﬁltration mechanism to remove cancer exosomes from the circulatory system• Allows selective exosome capture via unique high-mannose signatures resident on exosome surfaces
Providing access to the entire circulatory system• Exosomes can be accessed from entire circulatory system, which can pass through the Hemopuriﬁer® in as little as 15 minutes
Hemopuriﬁer® therapy has the advantage of beingdelivered through the global infrastructure of dialysismachines that are already located in hospitals in clinics
Our goal is to improve patient responsivenessto traditional chemotherapies and emergingclasses of immune based therapies
To improve patient responsiveness withoutadditional drug toxicity or interaction risks
In vitro binding of exosomes underlying thefollowing cancers has been demonstrated• Breast• Ovarian• Colorectal• Lymphoma• Melanoma
Human Hemopuriﬁer® treatment experience already exists
The Hemopuriﬁer® has previously demonstratedthe ability to reduce viral load in HIV andhepatitis C (HCV) infected individuals without theadministration of antiviral drugs
A clinical study to evaluate the ability of theHemopuriﬁer® to improve HCV drug therapybenefit is currently being conducted
The clinical application of the Hemopuriﬁer® in Cancer?
We are currently collaborating withcandidate investigators to develop a clinicalprotocol to demonstrate the ability of ourHemopuriﬁer® to eliminate circulatingcancer exosomes
We invite you to follow our efforts to improve cancer care AethlonMedical.com
Our mission is to create innovative devices thataddress unmet medical needs in cancer, infectiousdisease, and other life-threatening conditions Thank You
ContactJim JoyceChairman, CEO8910 University Center LaneSan Diego, California firstname.lastname@example.org
This presentation contains forward-looking statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995, and Aethlon Medical intends that such forward-looking statements besubject to the safe harbor created thereby. These statements are based on management’s currentexpectations and beliefs and are subject to a number of risks, uncertainties and assumptions that couldcause actual results to differ materially from those described. All statements, other than statements ofhistorical fact, are statements that could be deemed forward-looking statements, including the company’sability to successfully obtain FDA and other regulatory approvals for the sale of its products, thecapability of the Hemopuriﬁer® to reduce viral loads and other disease conditions or to identify or treatdisease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and theimpact that potential ability may have on disease conditions, and the company’s ability to raise capitalwhen needed. Some information in this presentation, or on which this presentation is based, has been obtained fromsources that Aethlon Medical, Inc., believes to be reliable and accurate. However, it has not beenindependently veriﬁed and no representation or warranty, express or implied, is made as to the accuracyor completeness of any information obtained from third parties. Such risks and uncertainties, including those discussed above, are more fully described in the Securitiesand Exchange Commission (SEC) reports ﬁled by Aethlon Medical, Inc., including its most recent annualreport on Form 10-K. This presentation speaks only as of its date, and the company disclaims any dutyto update the information herein. Further information is available by contacting the company or at thecompany’s website at www.aethlonmedical.com.
Gostou de algum slide específico?
Recortar slides é uma maneira fácil de colecionar informações para acessar mais tarde.